



Supplementary

Does Drug-Resistant Extrapulmonary Tuberculosis Hinder TB Elimination Plans? A Case from Delhi, India

Sheelu Lohiya ^{1,*}, Jaya Prasad Tripathy ², Karuna Sagili ³, Vishal Khanna ¹, Ravinder ⁴, Arun Ojha ¹, Anuj Bhatnagar ⁵ and Ashwani Khanna ¹

¹ Lok Nayak Hospital, New Delhi 110002, India; dr.vishalkhanna@rediffmail.com (V.K.); dpsdllnc@rntcp.org (A.O.); stodl@rntcp.org (A.K.)

² All India Institute of Medical Sciences, Nagpur 441108, India; ijay.doc@gmail.com

³ International Union Against Tuberculosis and Lung Disease, The Union South East Asia Office, New Delhi 110016, India; KSagili@theunion.org

⁴ All India Institute of Medical Sciences, New Delhi 110029, India; dpsdIndm@rntcp.org

⁵ Rajan Babu Institute of Pulmonary Medicine and Tuberculosis, New Delhi 110009 India; dpsdlkcc@rntcp.org

* Correspondence: dtodllnc@rntcp.org

Received: 11 March 2020; Accepted: 28 May 2020; Published: date

Table S1. Socio-demographic and clinical factors associated with unfavorable treatment outcome among drug resistant extra-pulmonary TB cases in Delhi aged < 15 years, 2016.

	Variables	Treatment Outcome			RR (95% CI)	p value
		Total N	Unfavorable n	%		
Sex	Male	21	5	(23.8)	1.0 (0.4–2.7)	0.9
	Female	29	7	(24.1)		
Weight (in Kilograms)	< 30	36	7	(19.4)	1.8 (0.7–4.8)	0.3
	31–50	14	5	(35.7)		
DR-TB Centre	Centre 1	15	1	(6.7)	3.6 (0.5–27.5)	0.3
	Centre 2	21	5	(23.8)		
	Centre3	14	6	(42.9)		
Site of disease	Others	22	3	(13.6)	0.4 (0.2–1.4)	0.13
	Lymph node	28	9	(32.1)		
Basis of diagnosis	Others	5	0	(0.0)	--	0.32
	CBNAAT	45	12	(26.7)		
History of previous TB	Yes	40	11	(27.5)	2.7 (0.4–18.9)	0.24
	No	10	1	(10.0)		
HIV status	Negative	48	11	(22.9)	1.0	0.4
	Positive	2	1	(50.0)		
Severe adverse reaction	Yes	7	1	(14.3)	0.6 (0.2–3.7)	0.5
	No	43	11	(25.6)		

RR: Relative Risk; DR-TB: Drug Resistant Tuberculosis; CBNAAT: Cartridge Based Nucleic Amplification Test; HIV: Human Immunodeficiency Virus.

Table S2. Socio-demographic and clinical factors associated with unfavorable treatment outcome among drug resistant extra-pulmonary TB cases in Delhi aged ≥15 years, 2016.

	Variables	Treatment Outcome			RR (95% CI)	p value
		Total N	Unfavorable n	%		
Sex	Male	71	30	(42.3)	1.3 (0.9–1.9)	0.2
	Female	82	27	(32.9)		
Age (years)	15–44 years	147	52	(35.4)	1.0	

	> 45 years	6	5	(83.3)	2.4 (1.6–3.6)	0.02
Weight (in Kilograms)	< 30	5	1	(20.0)	1.0	
	31–50	79	32	(40.5)	2.0 (0.3–12.0)	0.6
	Above 50	69	24	(34.8)	1.7 (0.3–10.0)	0.6
DR-TB Centre	Centre 1	44	15	(34.1)	1.0	
	Centre 2	67	32	(47.8)	1.4 (0.9–2.3)	0.1
	Centre 3	42	10	(23.8)	1.4 (0.7–2.8)	0.8
Site of disease	Others	82	35	(42.7)	1.4 (0.9–2.1)	0.1
	Lymph node	71	22	(31.0)	1.0	
Basis of diagnosis	Others	25	10	(40.0)	1.1 (0.6–1.8)	0.7
	CBNAAT	128	47	(36.7)	1.0	
History of previous TB	Yes	138	53	(38.4)	1.4 (0.6–3.4)	0.4
	No	15	4	(26.7)	1.0	
HIV status	Negative	152	56	(36.8)	1.0	0.3
	Positive	1	1	(100)	2.7 (2.2–3.3)	
Diabetes	Yes	5	3	(60.0)	1.6 (0.8–3.5)	0.3
	No	148	54	(36.5)	1.0	
Severe adverse reaction	Yes	51	15	(29.4)	0.7 (0.4–1.2)	0.2
	No	102	42	(41.2)		

RR: Relative Risk; DR-TB: Drug Resistant Tuberculosis; CBNAAT: Cartridge Based Nucleic Amplification Test; HIV: Human Immunodeficiency Virus.



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).